Neurocrine Biosciences takes up option on pediatric epilepsy candidate

12 May 2020

California-based neurology specialist Neurocrine Biosciences (Nasdaq: NBIX) has exercised its option to license the global rights of Swiss biotech Idorsia's (SIX: IDIA) ACT-709478. The decision follows the Investigational New Drug (IND) application acceptance by the US Food and Drug Administration.

Having hit 32.44 Swiss francs in early trading, Idorsia’s shares were still up more than 3% qt 31.86 francs in late afternoon trading today as a result of the announcement.

Neurocrine plans to initiate a Phase II study with this potent, selective, orally-active and brain penetrating T-type calcium channel blocker for the treatment of a rare pediatric epilepsy in the second half of 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK